Cabaletta Bio Inc logo

CABA - Cabaletta Bio Inc Share Price

$16.37 0.1  0.6%

Last Trade - 17/01/20

Sector
Healthcare
Size
Small Cap
Market Cap £302.5m
Enterprise Value £247.8m
Revenue £n/a
Position in Universe 3229th / 6415
Bullish
Bearish
Unlock CABA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CABA Revenue Unlock CABA Revenue

Net Income

CABA Net Income Unlock CABA Revenue

Normalised EPS

CABA Normalised EPS Unlock CABA Revenue

PE Ratio Range

CABA PE Ratio Range Unlock CABA Revenue

Dividend Yield Range

CABA Dividend Yield Range Unlock CABA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CABA EPS Forecasts Unlock CABA Revenue
Profile Summary

Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated April 3, 2017
Public Since October 25, 2019
No. of Shareholders: n/a
No. of Employees: 19
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 24,034,022
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CABA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to CABA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.